What is Meprasil Injection?
MEPRASIL 40mg Injection is prescribed for the treatment of acid-related gastrointestinal disorders, including:
- Gastroesophageal Reflux Disease (GERD): GERD is a chronic condition where stomach acid flows back into the esophagus, causing heartburn and irritation. MEPRASIL helps alleviate these symptoms by reducing stomach acid production.
- Peptic Ulcer Disease: MEPRASIL is effective in treating peptic ulcers caused by Helicobacter pylori infections or the overuse of non-steroidal anti-inflammatory drugs (NSAIDs). It can also help prevent ulcer-related bleeding.
- Zollinger-Ellison Syndrome: This rare condition results in excessive stomach acid production due to tumors in the pancreas or duodenum. MEPRASIL helps control this overproduction.
- Erosive Esophagitis: MEPRASIL is used to treat and heal damage to the esophagus caused by prolonged acid exposure.
- Stress Ulcers: In critically ill patients, MEPRASIL can be administered to prevent the formation of stress-induced stomach ulcers.
Meprasil 40mg Injection Ingredients
MEPRASIL 40mg Injection contains the active ingredient omeprazole.
Inactive Ingredients include Sodium hydroxide for pH adjustment and other stabilizers that aid in the medication’s delivery via intravenous injection.
How Meprasil 40mg Injection work
Meprasil 40mg injection works by blocking the action of the hydrogen-potassium ATPase enzyme, commonly referred to as the proton pump. This enzyme is located in the stomach’s parietal cells and is responsible for the secretion of gastric acid. By inhibiting the proton pump, MEPRASIL significantly decreases the production of stomach acid. This helps to alleviate symptoms of acid reflux, promote healing of ulcers, and prevent further damage to the gastrointestinal lining.
Meprasil 40mg Injection Dosage
The recommended dosage of MEPRASIL 40mg Injection depends on the specific condition being treated and the patient’s overall health. The typical dosage is:
For GERD and Peptic Ulcer Disease: 40mg once daily administered intravenously.
For Zollinger-Ellison Syndrome: The dosage may vary and can be higher depending on the severity of the condition.
How Meprasil 40mg Injection is used?
Administration is done intravenously by a healthcare professional over a period of 20-30 minutes.
The duration of treatment typically lasts a few days, after which patients are transitioned to an oral formulation for long-term therapy.
Meprasil 40mg Injection Side Effects
MEPRASIL 40mg Injection is generally well-tolerated, but like all medications, it may cause side effects in some individuals. Side effects include:
- Headache
- Nausea and Vomiting
- Diarrhea or Constipation
- Injection Site Reactions
- Dizziness
- Difficulty breathing
- Rash
- Swelling of the face or throat.
What is the main use of MEPRASIL 40mg Injection?
MEPRASIL is primarily used for the treatment of acid-related gastrointestinal conditions, particularly in patients who cannot take oral medications or need rapid relief from symptoms.
How quickly does MEPRASIL start to work?
MEPRASIL 40mg Injection starts reducing stomach acid within an hour, with peak effects observed within a few hours of administration. Symptom relief is usually noticeable within a day or two.
Can MEPRASIL 40mg Injection be used during pregnancy?
While MEPRASIL is generally considered safe during pregnancy, it should only be used if prescribed by a healthcare provider after evaluating the potential risks and benefits.
Is it safe to use MEPRASIL long-term?
MEPRASIL is typically used for short-term treatment when oral medications are not feasible. For long-term acid suppression, oral proton pump inhibitors are recommended. Long-term use of PPIs should be closely monitored by a healthcare professional.
Can I switch from IV to oral omeprazole?
Yes, once the patient is stable and able to take oral medications, MEPRASIL IV is typically switched to an oral PPI for continued treatment.
Where can you buy Meprasil 40mg Inj in Nigeria?
You can buy Meprasil 40mg Inj online at Drugstore.ng, Nigeria’s largest online pharmacy store.